文献速递乳腺病理细胞病理与分子病理

细胞学标本中microRNA表达预测淋巴细胞为主型乳腺癌

Prediction of lymphocyte-predominant breast cancer using microRNA expression in cytology specimens.
PubMed 文献 · Cancer Cytopathol · 2026-01-01

本研究纳入56例诊断时行细针穿刺细胞学的乳腺癌患者(28例LPBC和28例非LPBC),从细胞学涂片标本提取总RNA,用逆转录聚合酶链反应定量6种候选miRNA。结果显示6种miRNA在LPBC组表达均显著低于非LPBC组(均p < .05),ROC曲线分析显示AUC为0.673至0.790,多因素分析确定每种miRNA均为LPBC的独立诊断预测因子。结论认为细胞学样本的miRNA谱可客观识别LPBC。

要点

  • 6种miRNA在LPBC组表达均显著低于非LPBC组(均p < .05)。
  • miR-4485的AUC最高为0.790,miR-6510最低为0.673。
  • 每种miRNA均为LPBC的独立诊断预测因子。

核心结论

  • 细胞学样本的miRNA谱能够客观识别淋巴细胞为主型乳腺癌(LPBC)。

研究设计与样本

  • 研究纳入56例诊断时行细针穿刺细胞学的乳腺癌患者,其中LPBC 28例、非LPBC 28例。
  • 从细胞学涂片标本提取总RNA,用逆转录聚合酶链反应定量6种候选miRNA(miR-30a-3p、miR-187、miR-196b、miR-1247、miR-4485、miR-6510)。
  • 采用受试者工作特征曲线分析和逻辑回归模型评估识别LPBC的性能。

主要发现

  • 6种miRNA在LPBC组的表达水平均显著低于非LPBC组(均p < .05)。
  • ROC曲线分析显示中等至较高的诊断准确性,AUC分别为:miR-30a-3p 0.708、miR-187 0.739、miR-196b 0.783、miR-1247 0.777、miR-4485 0.790、miR-6510 0.673。
  • 多因素分析进一步确定每种miRNA均为LPBC的独立诊断预测因子。

临床怎么用

  • 特定miRNA表达模式可反映肿瘤免疫微环境,有望用于评估乳腺癌肿瘤浸润淋巴细胞状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tumor-infiltrating lymphocytes are prognostic and predictive biomarkers of breast cancer; however, conventional assessment is hindered by invasiveness and subjective evaluation, limiting clinical reproducibility. This study investigated the utility of microRNA (miRNA) profiles in predicting lymphocyte-predominant breast cancer (LPBC). METHODS: This study included 56 patients with breast cancer who underwent fine-needle aspiration cytology at the time of diagnosis (28 LPBC and 28 non-LPBC cases). Total RNA was extracted from cytology smear specimens, and the expression levels of six candidate miRNAs (miR-30a-3p, miR-187, miR-196b, miR-1247, miR-4485, and miR-6510) were quantified using reverse-transcriptase polymerase chain reaction. The performance in identifying LPBC was evaluated using receiver operating characteristic curve analysis and logistic regression models. RESULTS: All six miRNAs showed significantly lower expression levels in the LPBC group than in the non-LPBC group (all p < .05). Receiver operating characteristic curve analysis demonstrated moderate to high diagnostic accuracy, with an area under the curve of 0.708 for miR-30a-3p, 0.739 for miR-187, 0.783 for miR-196b, 0.777 for miR-1247, 0.790 for miR-4485, and 0.673 for miR-6510. Multivariate analysis further identified each miRNA as an independent diagnostic predictor for LPBC. CONCLUSIONS: miRNA profiling of cytologic samples enabled the objective identification of LPBC. These findings suggest that specific miRNA expression patterns reflect the tumor immune microenvironment and can be used to evaluate the status of tumor-infiltrating lymphocytes in breast cancer.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Kai A, Arihiro K, Shigematsu H, et al. Prediction of lymphocyte-predominant breast cancer using microRNA expression in cytology specimens. Cancer Cytopathol. 2026. PMID: 42137987. doi:10.1002/cncy.70114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。